Analysts See $-0.39 EPS for Neurotrope, Inc. (NTRP)

July 20, 2018 - By Michele Cranor

Neurotrope, Inc. (NASDAQ:NTRP) Logo

Analysts expect Neurotrope, Inc. (NASDAQ:NTRP) to report $-0.39 EPS on August, 8.They anticipate $0.40 EPS change or 50.63 % from last quarter’s $-0.79 EPS. After having $-0.25 EPS previously, Neurotrope, Inc.’s analysts see 56.00 % EPS growth. The stock decreased 2.63% or $0.27 during the last trading session, reaching $9.99. About 17,026 shares traded. Neurotrope, Inc. (NASDAQ:NTRP) has risen 50.16% since July 20, 2017 and is uptrending. It has outperformed by 37.59% the S&P500.

Neurotrope, Inc., a biopharmaceutical company, focuses on developing therapeutic and diagnostic technologies in the field of neurodegenerative diseases in the United States. The company has market cap of $79.00 million. The companyÂ’s lead product candidate is bryostatin-1, a natural product isolated from a marine invertebrate organism, which is in a Phase II trial for the treatment of moderate to severe AlzheimerÂ’s dementia, as well as in preclinical studies as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease, and Rett Syndrome. It currently has negative earnings. It has a license agreement with the Leland Stanford Junior University to sublicense Bryologs that are structural derivatives of Bryostatin for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate, NRV II, LLC.

More recent Neurotrope, Inc. (NASDAQ:NTRP) news were published by: which released: “Global Neurological Devices Market to Rise and Hit $13.6 Billion in 2019” on June 25, 2018. Also published the news titled: “Neurotrope Returns After ‘Failed’ Alzheimer’s Trial, But Has Anything Changed?” on July 17, 2018.‘s news article titled: “Neurotrope (NTRP) Reports Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer’s Disease” with publication date: July 16, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.